LVTX LAVA Therapeutics NV

Nasdaq lavatherapeutics.com


$ 1.62 $ 0.00 (-0.31 %)    

Tuesday, 04-Nov-2025 14:39:16 EST
QQQ $ 618.00 $ -12.83 (-2.03 %)
DIA $ 471.47 $ -2.57 (-0.54 %)
SPY $ 674.81 $ -8.10 (-1.19 %)
TLT $ 89.98 $ 0.20 (0.22 %)
GLD $ 362.08 $ -6.46 (-1.75 %)
$ 1.625
$ 1.61
$ 1.58 x 20
$ 1.65 x 110
$ 1.60 - $ 1.63
$ 0.85 - $ 2.00
61,067
na
42.88M
$ 0.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- Amendment includes finalized cash amount and updated CVR terms for tender offer- LAVA announces new date for extraordinary ge...

Core News & Articles

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (&...

 4-biotech-stocks-that-are-showing-weakness-momentum-scores-fading-over-the-past-week

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stoc...

 hc-wainwright--co-maintains-neutral-on-lava-therapeutics-lowers-price-target-to-124

HC Wainwright & Co. analyst Arthur He maintains LAVA Therapeutics (NASDAQ:LVTX) with a Neutral and lowers the price targ...

 jefferies-downgrades-lava-therapeutics-to-hold-lowers-price-target-to-15

Jefferies analyst Roger Song downgrades LAVA Therapeutics (NASDAQ:LVTX) from Buy to Hold and lowers the price target from $3...

 jmp-securities-reiterates-market-perform-on-lava-therapeuticsto-market-perform

JMP Securities analyst Reni Benjamin reiterates LAVA Therapeutics (NASDAQ:LVTX) from Market Perform to Market Perform.

 lava-therapeutics-q1-eps-013-beats-038-estimate

LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-reiterates-neutral-on-lava-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Arthur He reiterates LAVA Therapeutics (NASDAQ:LVTX) with a Neutral and maintains $1.5 price...

 analyst-downgrades-lava-therapeutics-sees-pipeline-overhang

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266...

 hc-wainwright--co-downgrades-lava-therapeutics-to-neutral-lowers-price-target-to-15

HC Wainwright & Co. analyst Arthur He downgrades LAVA Therapeutics (NASDAQ:LVTX) from Buy to Neutral and lowers the pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION